Research ReportDevelopment/Plasticity/Repair Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during Myelination https://doi.org/10.1523/JNEUROSCI.1434-18.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.1434-18.2020 Received: 31 May 2018 Revised: 23 February 2020 Accepted: 26 February 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 Musah et al. 1 Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during 2 Myelination 3 1Aminat S. Musah, 2Tanya L. Brown, 1Marisa A. Jeffries, 1Quan Shang, 2Hirokazu Hashimoto, 4 1Angelina V. Evangelou, 3Alison Kowalski, 3Mona Batish, 2Wendy B. Macklin and 1Teresa L. 5 Wood 6 1Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, 7 Rutgers University, Newark, NJ U.S.A. 07101, 2Department of Cell and Developmental Biology, 8 University of Colorado School of Medicine, Aurora, CO, U.S.A. 80045, 3Department of Medical 9 and Molecular Sciences, University of Delaware, Newark, DE 19716 10 11 Abbreviated Title: mTOR Regulates the Oligodendrocyte Cytoskeleton 12 Corresponding Author: Teresa L. Wood, PhD, Department Pharmacology, Physiology & 13 Neuroscience, New Jersey Medical School Cancer Center H1200, Rutgers University, 205 S. 14 Orange Ave, Newark, NJ 07101-1709 15
[email protected] 16 Number of pages: 39 17 Number of Figures: 10 18 Number of Tables: 0 19 Number of Words: 20 Abstract: 242 21 Introduction: 687 22 Discussion: 1075 23 Conflict of Interest: The authors declare no competing financial interests.